ClinicalTrials.gg
Drug

Amrubicin clinical trials

Also written Calsed and SM-5887.

studies test it
17
open now
1
in phase 3
4
first study started
2004

How each study uses amrubicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the amrubicin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Amrubicin
13
Amrubicin Hydrochloride
3

Brand

Calsed
2

Development codes

SM-5887
2
CNF3140
1

Studies by the year they started

16 studies that test it; most in 2006 (4)

Studies that test amrubicin, by start year
YearStudies
20041
20064
20071
20081
20094
20114
20251

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
10
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 8

Celgene (4) · SCRI Development Innovations, LLC (2) · Celgene Corporation (2) · Heather Wakelee (1) · Michaela Liedtke (1) · University of Utah (1) · Lawrence Einhorn (1) · Sumitomo Pharma (Suzhou) Co., Ltd. (1)

Often tested with

Tested in the same studies.

Cisplatin (1) · Irinotecan (1) · Sacituzumab govitecan (1) · Topotecan (1) · PM 01183 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Amrubicin is the comparator. A study of two new drugs counts under both.

Studies

Open first, then newest update. How each study uses amrubicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

As the comparator · 5 — what is tested is compared with amrubicin

Codes

What other systems call amrubicin · ClinicalTrials.gg INT003376

  • MeSH (NLM) C055866amrubicinConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 93N13LB4Z2AMRUBICINConfirmed FDA, NLM, Wikidata
  • Wikidata Q4748723amrubicinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C80089AmrubicinOne source FDA
  • DrugBank DB06263One source Wikidata

Also registered as amrubicin hydrochloride (UNII EUL6MP8FZW).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.